|
SG11201400513PA
(en)
|
2011-09-08 |
2014-06-27 |
Yeda Res & Dev |
Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
|
|
AU2016291825B2
(en)
|
2015-07-16 |
2022-08-11 |
Yeda Research And Development Co. Ltd. |
Genetically modified anti-third party central memory T cells and use of same in immunotherapy
|
|
KR102634093B1
(ko)
|
2016-10-28 |
2024-02-07 |
브리스톨-마이어스 스큅 컴퍼니 |
항-pd-1 항체를 사용하여 요로상피 암종을 치료하는 방법
|
|
CN110072890B
(zh)
|
2016-11-03 |
2022-11-29 |
百时美施贵宝公司 |
可活化的抗ctla-4抗体及其用途
|
|
ES3064681T3
(en)
|
2017-01-18 |
2026-04-28 |
Yeda Res & Dev |
Genetically modified veto cells and use of same in immunotherapy
|
|
EP3601355A1
(en)
|
2017-03-31 |
2020-02-05 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
WO2018222718A1
(en)
|
2017-05-30 |
2018-12-06 |
Bristol-Myers Squibb Company |
Treatment of lag-3 positive tumors
|
|
JP7301002B2
(ja)
|
2017-05-30 |
2023-06-30 |
ブリストル-マイヤーズ スクイブ カンパニー |
抗lag-3抗体または抗lag-3抗体および抗pd-1もしくは抗pd-l1抗体を含む組成物
|
|
JP2020522495A
(ja)
|
2017-05-30 |
2020-07-30 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
抗lag−3抗体、pd−1経路阻害剤および免疫療法剤の組み合わせを含む組成物
|
|
EP3630840A1
(en)
|
2017-06-01 |
2020-04-08 |
Bristol-Myers Squibb Company |
Methods of treating a tumor using an anti-pd-1 antibody
|
|
US11351163B2
(en)
|
2017-09-29 |
2022-06-07 |
Bristol-Myers Squibb Company |
Compositions and methods of treating cancer
|
|
EP3694884A1
(en)
|
2017-10-15 |
2020-08-19 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
KR20200084880A
(ko)
|
2017-11-06 |
2020-07-13 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
KR20200109339A
(ko)
|
2018-01-16 |
2020-09-22 |
브리스톨-마이어스 스큅 컴퍼니 |
Tim3에 대한 항체를 사용하여 암을 치료하는 방법
|
|
AU2019210332A1
(en)
|
2018-01-22 |
2020-09-10 |
Pascal Biosciences Inc. |
Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
|
|
SG11202006823XA
(en)
|
2018-01-22 |
2020-08-28 |
Bristol Myers Squibb Co |
Compositions and methods of treating cancer
|
|
AU2019240370B2
(en)
*
|
2018-03-23 |
2024-03-07 |
Gavish-Galilee Bio Applications Ltd. |
Genetically reprogrammed Tregs expressing membrane-bound IL-10
|
|
JP7351845B2
(ja)
|
2018-03-23 |
2023-09-27 |
ブリストル-マイヤーズ スクイブ カンパニー |
Micaおよび/またはmicbに対する抗体ならびにそれらの使用
|
|
EP3774911A1
(en)
|
2018-03-30 |
2021-02-17 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
EP3774903A1
(en)
|
2018-04-04 |
2021-02-17 |
Bristol-Myers Squibb Company |
Anti-cd27 antibodies and uses thereof
|
|
JP7097465B2
(ja)
*
|
2018-06-19 |
2022-07-07 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
キメラ抗原受容体細胞療法と併用するil-10剤の組成およびその使用方法
|
|
AU2019309849A1
(en)
|
2018-07-26 |
2021-03-18 |
Bristol-Myers Squibb Company |
LAG-3 combination therapy for the treatment of cancer
|
|
EP3842550A4
(en)
*
|
2018-08-24 |
2022-06-29 |
Repertoire Genesis Incorporation |
Method for analyzing functional subunit pair gene of t cell receptor and b cell receptor
|
|
US20210395392A1
(en)
|
2018-10-09 |
2021-12-23 |
Bristol-Myers Squibb Company |
Anti-mertk antibodies for treating cancer
|
|
WO2020081928A1
(en)
|
2018-10-19 |
2020-04-23 |
Bristol-Myers Squibb Company |
Combination therapy for melanoma
|
|
JP2022505647A
(ja)
|
2018-10-23 |
2022-01-14 |
ブリストル-マイヤーズ スクイブ カンパニー |
腫瘍の処置方法
|
|
MX2021005708A
(es)
|
2018-11-16 |
2021-09-21 |
Bristol Myers Squibb Co |
Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
|
|
MX2021006578A
(es)
*
|
2018-12-05 |
2021-07-07 |
Genentech Inc |
Procedimientos de diagnostico y composiciones para la inmunoterapia contra el cancer.
|
|
CN109735558B
(zh)
*
|
2018-12-12 |
2022-04-15 |
中南大学 |
一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用
|
|
WO2020198676A1
(en)
|
2019-03-28 |
2020-10-01 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
KR20210146348A
(ko)
|
2019-03-28 |
2021-12-03 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
JP2022534982A
(ja)
|
2019-05-30 |
2022-08-04 |
ブリストル-マイヤーズ スクイブ カンパニー |
細胞局在化シグネチャーおよびその使用
|
|
WO2020243570A1
(en)
|
2019-05-30 |
2020-12-03 |
Bristol-Myers Squibb Company |
Cell localization signature and combination therapy
|
|
US20220363760A1
(en)
|
2019-05-30 |
2022-11-17 |
Bristol-Myers Squibb Company |
Multi-tumor gene signature for suitability to immuno-oncology therapy
|
|
JP7337373B2
(ja)
*
|
2019-07-29 |
2023-09-04 |
サイアス株式会社 |
抗原特異的t細胞の製造方法
|
|
WO2021055994A1
(en)
|
2019-09-22 |
2021-03-25 |
Bristol-Myers Squibb Company |
Quantitative spatial profiling for lag-3 antagonist therapy
|
|
CN114728070A
(zh)
|
2019-09-25 |
2022-07-08 |
百时美施贵宝公司 |
用于癌症疗法的复合生物标记物
|
|
WO2021092044A1
(en)
|
2019-11-05 |
2021-05-14 |
Bristol-Myers Squibb Company |
M-protein assays and uses thereof
|
|
WO2021092220A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
WO2021092221A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
EP4054723A1
(en)
|
2019-11-08 |
2022-09-14 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for melanoma
|
|
WO2021097256A1
(en)
|
2019-11-14 |
2021-05-20 |
Cohbar, Inc. |
Cxcr4 antagonist peptides
|
|
WO2021127554A1
(en)
|
2019-12-19 |
2021-06-24 |
Bristol-Myers Squibb Company |
Combinations of dgk inhibitors and checkpoint antagonists
|
|
AU2021213969A1
(en)
|
2020-01-30 |
2022-09-01 |
ONA Therapeutics S.L. |
Combination therapy for treatment of cancer and cancer metastasis
|
|
WO2021158938A1
(en)
|
2020-02-06 |
2021-08-12 |
Bristol-Myers Squibb Company |
Il-10 and uses thereof
|
|
WO2021176424A1
(en)
|
2020-03-06 |
2021-09-10 |
Ona Therapeutics, S.L. |
Anti-cd36 antibodies and their use to treat cancer
|
|
AU2021244200A1
(en)
|
2020-03-23 |
2022-11-24 |
Bristol-Myers Squibb Company |
Anti-CCR8 antibodies for treating cancer
|
|
US20210393743A1
(en)
*
|
2020-06-21 |
2021-12-23 |
Ketan Desai |
Use of IL13 for prevention and treatment of COVID19
|
|
MX2023002332A
(es)
|
2020-08-28 |
2023-03-21 |
Bristol Myers Squibb Co |
Terapia con antagonistas del gen 3 de activacion de linfocitos (lag-3) para carcinoma hepatocelular.
|
|
IL300916A
(en)
|
2020-08-31 |
2023-04-01 |
Bristol Myers Squibb Co |
Cell localization signature and immunotherapy
|
|
JP2023544410A
(ja)
|
2020-10-05 |
2023-10-23 |
ブリストル-マイヤーズ スクイブ カンパニー |
タンパク質を濃縮するための方法
|
|
CA3196496A1
(en)
|
2020-10-23 |
2022-04-28 |
Laurence David TOMS |
Lag-3 antagonist therapy for lung cancer
|
|
CA3196535A1
(en)
|
2020-10-28 |
2022-05-05 |
Alfredo C. Castro |
Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
PT4267105T
(pt)
|
2020-12-28 |
2025-04-30 |
Bristol Myers Squibb Co |
Composições de anticorpos e métodos de utilização das mesmas
|
|
AU2021416156A1
(en)
|
2020-12-28 |
2023-06-22 |
Bristol-Myers Squibb Company |
Methods of treating tumors
|
|
CN117858719A
(zh)
|
2021-03-29 |
2024-04-09 |
朱诺治疗学股份有限公司 |
使用检查点抑制剂疗法和car t细胞疗法的组合进行给药和治疗的方法
|
|
JP2024514530A
(ja)
|
2021-04-02 |
2024-04-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
切断型cdcp1に対する抗体およびその使用
|
|
CA3226281A1
(en)
|
2021-07-30 |
2023-02-02 |
ONA Therapeutics S.L. |
Anti-cd36 antibodies and their use to treat cancer
|
|
WO2023077090A1
(en)
|
2021-10-29 |
2023-05-04 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for hematological cancer
|
|
AU2023213937A1
(en)
|
2022-01-26 |
2024-07-18 |
Bristol-Myers Squibb Company |
Combination therapy for hepatocellular carcinoma
|
|
KR20240153583A
(ko)
|
2022-02-25 |
2024-10-23 |
브리스톨-마이어스 스큅 컴퍼니 |
결장직장암종에 대한 병용 요법
|
|
WO2023168404A1
(en)
|
2022-03-04 |
2023-09-07 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
|
CN119156403A
(zh)
|
2022-03-08 |
2024-12-17 |
阿伦蒂斯治疗股份公司 |
抗紧密连接蛋白-1抗体增加t细胞可用性的用途
|
|
US20250206775A1
(en)
|
2022-03-18 |
2025-06-26 |
Bristol-Myers Squibb Company |
Methods of isolating polypeptides
|
|
WO2023196987A1
(en)
|
2022-04-07 |
2023-10-12 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
JP7851417B2
(ja)
|
2022-04-08 |
2026-04-24 |
ブリストル-マイヤーズ スクイブ カンパニー |
三次リンパ組織様構造の機械学習識別、分類、及び定量化
|
|
AU2023281061A1
(en)
|
2022-06-02 |
2024-12-05 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
|
EP4310197A1
(en)
|
2022-07-21 |
2024-01-24 |
Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda |
Method for identifying lung cancer patients for a combination treatment of immuno- and chemotherapy
|
|
CN120379691A
(zh)
|
2022-09-30 |
2025-07-25 |
爱兰蒂斯疗法股份公司 |
耐药性肝细胞癌的治疗
|
|
AU2023403103A1
(en)
|
2022-12-01 |
2025-07-10 |
Medimmune Limited |
Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies
|
|
KR20250123912A
(ko)
|
2022-12-21 |
2025-08-18 |
브리스톨-마이어스 스큅 컴퍼니 |
폐암에 대한 병용 요법
|
|
WO2024150177A1
(en)
|
2023-01-11 |
2024-07-18 |
Advesya |
Treatment methods for solid tumors
|
|
WO2024196952A1
(en)
|
2023-03-20 |
2024-09-26 |
Bristol-Myers Squibb Company |
Tumor subtype assessment for cancer therapy
|
|
WO2024261239A1
(en)
|
2023-06-23 |
2024-12-26 |
Imcheck Therapeutics |
Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis
|
|
CN121712571A
(zh)
|
2023-08-15 |
2026-03-20 |
百时美施贵宝公司 |
陶瓷羟基磷灰石色谱流通法
|
|
CN122459678A
(zh)
|
2023-12-29 |
2026-07-24 |
百时美施贵宝公司 |
KRAS抑制剂与Treg耗竭剂的组合疗法
|
|
US12521446B2
(en)
|
2024-02-27 |
2026-01-13 |
Bristol-Myers Squibb Company |
Anti-CEACAM5 antibody drug conjugates
|
|
US20250361320A1
(en)
|
2024-02-27 |
2025-11-27 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibodies and uses thereof
|
|
WO2025245489A1
(en)
|
2024-05-24 |
2025-11-27 |
Bristol-Myers Squibb Company |
Treatment of tumors in subjects having fgl-1 positive samples
|
|
WO2026096695A1
(en)
|
2024-10-31 |
2026-05-07 |
Bristol-Myers Squibb Company |
Anti-fucosyl-gm1 antibody drug conjugates
|
|
US20260144885A1
(en)
|
2024-11-22 |
2026-05-28 |
Bristol-Myers Squibb Company |
Anti-lrrc15 antibodies and uses thereof
|
|
US20260144884A1
(en)
|
2024-11-22 |
2026-05-28 |
Bristol-Myers Squibb Company |
Anti-lrrc15 antibody drug conjugates
|